Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

KARUNA THERAPEUTICS, INC.

(KRTX)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
200.01 USD   -0.39%
12/06Sector Update: Health Care Stocks Fall but Outperform Most Other Sectors
MT
12/06Karuna Therapeutics Appoints Bill Meury as Chief Executive, Christopher Coughlin as Chairman; Shares Drop
MT
12/06Sector Update: Health Care Stocks Largely Resisting Steep Declines
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
229.98(c) 236.82(c) 226.95(c) 200.79(c) 200.01(c) Last
229 439 304 351 240 291 1 149 781 356 348 Volume
-2.27% +2.97% -4.17% -11.53% -0.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4,79 M - -
Net income 2022 -273 M - -
Net cash position 2022 960 M - -
P/E ratio 2022 -23,0x
Yield 2022 -
Sales 2023 22,8 M - -
Net income 2023 -316 M - -
Net cash position 2023 860 M - -
P/E ratio 2023 -21,4x
Yield 2023 -
Capitalization 6 873 M 6 873 M -
EV / Sales 2022 1 233x
EV / Sales 2023 263x
Nbr of Employees 118
Free-Float 94,3%
More Financials
Company
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for... 
More about the company
Ratings of Karuna Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about KARUNA THERAPEUTICS, INC.
12/06Sector Update: Health Care Stocks Fall but Outperform Most Other Sectors
MT
12/06Karuna Therapeutics Appoints Bill Meury as Chief Executive, Christopher Coughlin as Cha..
MT
12/06Sector Update: Health Care Stocks Largely Resisting Steep Declines
MT
12/06Sector Update: Health Care
MT
12/06Karuna Therapeutics, Inc. : Change in Directors or Principal Officers, Regulation FD Discl..
AQ
12/06Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
BU
12/06Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023
CI
12/06Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023
CI
12/02Insider Sell: Karuna Therapeutics
MT
11/17Insider Sell: Karuna Therapeutics
MT
11/14Insider Sell: Karuna Therapeutics
MT
11/07Oppenheimer Adjusts Karuna Therapeutics Price Target to $280 From $285, Maintains Outpe..
MT
11/04RBC Cuts Price Target on Karuna Therapeutics to $286 From $293, Maintains Outperform, S..
MT
11/04Insider Sell: Karuna Therapeutics
MT
11/03KARUNA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
More news
News in other languages on KARUNA THERAPEUTICS, INC.
12/06Mise à jour sectorielle : Les actions du secteur de la santé chu..
12/06Karuna Therapeutics nomme Bill Meury au poste de directeur général et Christopher Cough..
12/06Mise à jour sectorielle : Les actions du secteur de la santé rés..
12/06Mise à jour sectorielle : Soins de santé
12/06Karuna Therapeutics, Inc. annonce des changements au sein de sa direction, à compter du..
More news
Analyst Recommendations on KARUNA THERAPEUTICS, INC.
More recommendations
ETFs positioned on KARUNA THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ALPS Medical Breakthroughs ETF - USD2.29%-4.81%United_States
Virtus LifeSci Biotech Clinical Trials ETF - USD1.41%-3.85%United_States
SPDR S&P Biotech ETF - USD1%0.76%United_States
ETFs S&P Biotech ETF - Distributing - AUD1%-2.34%-United_States
Invesco Nasdaq Biotechnology ETF - USD0.83%0.80%-United_States
More ETFs positioned on KARUNA THERAPEUTICS, INC.
Chart KARUNA THERAPEUTICS, INC.
Duration : Period :
Karuna Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARUNA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 200,01 $
Average target price 290,72 $
Spread / Average Target 45,4%
EPS Revisions
Managers and Directors
Steven Marc Paul Chairman, President & Chief Executive Officer
Troy A. Ignelzi Chief Financial Officer & Secretary
Stephen Brannan Chief Medical Officer
Inder Kaul Vice President-Clinical Development
Ronald Marcus Senior Vice President-Medical
Sector and Competitors
1st jan.Capi. (M$)
KARUNA THERAPEUTICS, INC.53.27%6 873
REGENERON PHARMACEUTICALS, INC.18.36%81 626
VERTEX PHARMACEUTICALS41.99%81 520
BIONTECH SE-36.92%39 522
WUXI APPTEC CO., LTD.-33.48%32 802
GENMAB A/S23.27%29 855